Seeking Breakthrough Therapies for Immuno-Inflammatory DiseasesJune 2, 2022
There are about 1 million people with ulcerative colitis in the U.S. today and only approximately 14 percent of them achieve long-term remission with the current standard of care. The unmet need for treatments means many with the chronic and often debilitating inflammatory bowel disease desperately need new treatment options.
The results of Phase 3 trials of etrasimod, a daily, oral therapy candidate from Pfizer for the potential treatment of moderately to severely active ulcerative colitis, were presented recently in a scientific forum and based on those findings the company plans to seek regulatory approval later this year.
Additional information for Pfizer investors can be found here.
Etrasimod was developed by Arena Pharmaceuticals, which was recently acquired by Pfizer. The Arena transaction builds upon Pfizer’s existing areas of focus and expands the company’s research and development portfolio of potential innovative therapies for the treatment of immuno-inflammatory conditions with promising developmental-stage therapeutic candidates in gastroenterology, dermatology and cardiology.
Pfizer plans to leverage its global research and development capabilities to accelerate clinical development of the portfolio and create potentially new, differentiated breakthrough therapies that change the lives of people living with immuno-inflammatory diseases.
 Seyedian, SS. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113-122. Available at: A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease – PMC (nih.gov). Accessed April 26, 2022.